Ponatinib
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-PONATINIB |
|---|---|
| Type | Drug |
| Aliases | IclusigПонатиніб |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-CML |
| Sources | SRC-ELN-CML-2020 SRC-NCCN-MPN-2025 |
Drug Facts
| Class | BCR-ABL1 TKI (3rd-generation, T315I-active) |
|---|---|
| Mechanism | Pan-BCR-ABL1 TKI active against ALL known kinase-domain mutations including T315I gatekeeper. Reserved for r/r CML/Ph+ ALL after multiple TKI failures or T315I emergence due to substantial vascular toxicity. |
| Typical dosing | CML/Ph+ ALL with T315I or post multiple TKI failures: starting 45 mg PO daily; reduce to 15 mg upon achievement of major molecular response (response-adjusted dosing per OPTIC trial reduces vascular events ~50%). |
| Ukraine registered | False |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-04-27 |
Warnings
- Arterial occlusive events (boxed) — MI, stroke, PAOD; mortality risk
- Heart failure
- Hepatotoxicity
Notes
Reserved for T315I CML or post ≥2 TKI failures. Response-adjusted dosing (45 → 15 mg upon MMR) per OPTIC trial reduces toxicity. Asciminib (STAMP) is an emerging less-toxic alternative for similar indication. NOT registered in Ukraine — major access barrier.
Used By
Regimens
REG-PONATINIB-CML- Ponatinib for CML T315I+ OR post ≥2 TKI failure